SirnaMed Therapeutics is a pioneering biotechnology company driven by the vision of inventing a future without cancer. We are developing a novel class of RNA interference (RNAi) therapeutics that leverage advanced polymeric nanoparticles to deliver potent siRNA molecules directly to tumor sites. Our proprietary platform overcomes the limitations of current cancer therapies by achieving unprecedented tumor penetration and sustained release of siRNA, enabling precise and targeted gene silencing. We are focused on developing a pipeline of first-in-class therapies for a range of challenging treatment-resistant cancers, with the goal of providing transformative treatments for patients in needs